AT142258T - human vascular permeability factor - Google Patents

human vascular permeability factor

Info

Publication number
AT142258T
AT142258T AT89870181T AT89870181T AT142258T AT 142258 T AT142258 T AT 142258T AT 89870181 T AT89870181 T AT 89870181T AT 89870181 T AT89870181 T AT 89870181T AT 142258 T AT142258 T AT 142258T
Authority
AT
Austria
Prior art keywords
vascular permeability
human vascular
permeability factor
factor
human
Prior art date
Application number
AT89870181T
Other languages
German (de)
Inventor
Pamela Jean Keck
Joseph Feder
Daniel Thomas Connolly
Jitka Vera Olander
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US27406188A priority Critical
Priority to US07/377,037 priority patent/US5240848A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AT142258T publication Critical patent/AT142258T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
AT89870181T 1988-11-21 1989-11-20 human vascular permeability factor AT142258T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US27406188A true 1988-11-21 1988-11-21
US07/377,037 US5240848A (en) 1988-11-21 1989-07-10 Dna sequences encoding human vascular permeability factor having 189 amino acids

Publications (1)

Publication Number Publication Date
AT142258T true AT142258T (en) 1996-09-15

Family

ID=26956578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89870181T AT142258T (en) 1988-11-21 1989-11-20 human vascular permeability factor

Country Status (7)

Country Link
US (1) US5240848A (en)
EP (1) EP0370989B1 (en)
JP (2) JP2567114B2 (en)
AT (1) AT142258T (en)
DE (2) DE68927088T2 (en)
ES (1) ES2031806T3 (en)
GR (1) GR3021708T3 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0464155T3 (en) * 1989-03-24 1997-11-17 Univ California An endothelial cell growth, the isolation and expression
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2017379C (en) * 1989-05-24 2002-06-25 Kenneth A. Thomas, Jr. Purification and characterization of a glioma-derived growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69229454T2 (en) * 1991-03-28 2000-01-05 Merck & Co Inc Subunit C of vascular endothelial cell growth factor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP3172841B2 (en) * 1992-02-19 2001-06-04 株式会社日立製作所 TFT and its manufacturing method and a liquid crystal display device
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CN1267550C (en) 1994-03-08 2006-08-02 人体基因组科学有限公司 Vascular endothelial growth factor 2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
DE69736860D1 (en) 1996-09-24 2006-12-07 Merck & Co Inc Compounds for inhibiting angiogenesis through gene therapy
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP2001509168A (en) 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド Multi-site delivery of adenovirus vectors to induce angiogenesis
CA2293723A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
US20030054400A1 (en) * 1997-09-17 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK2042597T3 (en) 2000-06-23 2014-08-11 Genentech Inc Compositions and procedures for diagnosis and treatment of diseases involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
IL137616D0 (en) 1998-02-06 2001-07-24 Collateral Therapeutics Inc Variants of vegf-a
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO1999047677A2 (en) 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US7344880B2 (en) * 1998-04-24 2008-03-18 Genentech, Inc. Nucleic acid encoding PRO9912 polypeptides
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
DK1112083T3 (en) 1998-09-09 2004-03-08 Univ Washington Treatment of microvascular angiopathies
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
DE60011612T2 (en) 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Compositions and methods of cancer treatment by the selective inhibition of VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1183357A2 (en) * 1999-05-20 2002-03-06 Scios Inc. Vascular endothelial growth factor dimers
AU5023300A (en) 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
US7365157B2 (en) * 1999-12-23 2008-04-29 Genentech, Inc. PRO9912 polypeptides
US7164001B2 (en) * 2000-01-20 2007-01-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1313512A4 (en) * 2000-08-04 2004-08-25 Human Genome Sciences Inc Vascular endothelial growth factor 2
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
KR20030093316A (en) * 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CN101884784B (en) * 2001-08-29 2014-03-12 杰南技术公司 Bv8 nucleic acids and polypeptides with mitogenic activity
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
DK2308507T3 (en) * 2002-07-19 2015-04-20 Beth Israel Hospital Methods for the treatment of preeclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
EP1590436A4 (en) * 2003-01-29 2006-08-02 Merck & Co Inc Rat receptor tyrosine kinase, kdr
NZ541480A (en) 2003-03-12 2008-03-28 Genentech Inc Use of Bv8 and/or EG-VEGF to promote hematopoiesis
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
WO2005084329A2 (en) * 2004-03-02 2005-09-15 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AR050608A1 (en) * 2004-08-19 2006-11-08 Alza Corp Apparatus and method for transdermal administration of vascular endothelial growth factors
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP2347765B1 (en) * 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
EP1839057B1 (en) * 2004-12-15 2010-08-25 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
EP2314614B1 (en) 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
JP2008537752A (en) * 2005-04-12 2008-09-25 イントラディグム コーポレイション RNAi therapeutic compositions and methods for treating cancer and other neovascular diseases
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20060287234A1 (en) * 2005-06-17 2006-12-21 Genentech, Inc. Wound healing
WO2007024752A2 (en) * 2005-08-26 2007-03-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
JP5959506B2 (en) 2010-05-14 2016-08-02 ベス イスラエル デアコネス メディカル センター インコーポレイテッド Extracorporeal devices and methods for treating pregnancy complications
CA2980339A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5038003A (en) * 1990-05-14 1991-08-06 T & B Industries, Inc. Waterproof electrical splice enclosure with specialized housing to prevent the wires from being removed from the waterproof material within the housing

Also Published As

Publication number Publication date
GR3021708T3 (en) 1997-02-28
JP2783385B2 (en) 1998-08-06
DE68927088T2 (en) 1997-02-20
ES2031806T1 (en) 1993-01-01
US5240848A (en) 1993-08-31
EP0370989A3 (en) 1991-10-09
EP0370989B1 (en) 1996-09-04
EP0370989A2 (en) 1990-05-30
DE68927088D1 (en) 1996-10-10
JPH02282398A (en) 1990-11-19
ES2031806T3 (en) 1997-01-01
JP2567114B2 (en) 1996-12-25
JPH0923887A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
FI103383B (en) The catheter needleguard
DE68928754D1 (en) Collagen-polymer-conjugates
DE68928345T2 (en) Confokales scan-endoscope
DE68928260T2 (en) Spektralkombinationsvorrichtung
DE58906403D1 (en) Tissue adhesive.
DE3876417D1 (en) Once filter.
DE68917895T2 (en) Catheter.
DE3752004T2 (en) catheter
DE68918943T2 (en) Gewebeentzusammensetzung and procedures.
DE3885439D1 (en) Catheter.
DK152489A (en) Tandtraad
DK712988D0 (en) Kombinationsdyvel
DK305390D0 (en) 11beta-substituted progesteronanaloger
DK182490A (en) Kosmetikdispenseranlaeg
DK106891D0 (en) Tabsdetektion
DK154290A (en) Batterikapsling
DK591389A (en) Lamelportfloej
DK69292D0 (en) Batteriovervaagningssystem
DE68926862D1 (en) Balloon catheter assembly
DE68922887T2 (en) Composite vascular catheter.
DK461989D0 (en) Flammesproejteapparat
DK416389A (en) Phosphorsyrebraendselscellekraftanlaeg
DE68927907T2 (en) Einchipmikrorechner
DE68915878T2 (en) Vascular catheter.
DE3882126T2 (en) Artificial respirator.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time